Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics has announced that the United States Adopted Names (USAN) Council has approved ‘narmafotinib’ as the nonproprietary name for its lead FAK inhibitor, which is undergoing clinical trials for pancreatic cancer. This approval is a critical milestone in the drug’s commercial development, coinciding with the initiation of a clinical trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia. The trial aims to explore the drug’s safety, tolerability, and efficacy, potentially enhancing Amplia’s positioning in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, and FAK also plays a significant role in chronic diseases like idiopathic pulmonary fibrosis.
YTD Price Performance: 85.39%
Average Trading Volume: 7,254,682
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
See more data about ATX stock on TipRanks’ Stock Analysis page.